Amyotrophic Lateral Sclerosis News and Research

RSS

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001.

1 Jul 2015

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative.

1 Jul 2015

Kay E. Davies named recipient of ASHG's 2015 William Allan Award

The American Society of Human Genetics has named Kay E. Davies, DPhil, Dr. Lee's professor of anatomy, associate head of the medical sciences division; and director of the Medical Research Council Functional Genomics Unit in the department of physiology, anatomy and genetics at the University of Oxford, the 2015 recipient of the annual William Allan Award.

30 Jun 2015

Stanford researchers find how neurons work together to control movement in people with paralysis

Stanford University researchers studying how the brain controls movement in people with paralysis, related to their diagnosis of Lou Gehrig's disease, have found that groups of neurons work together, firing in complex rhythms to signal muscles about when and where to move.

24 Jun 2015

Novel combination of non-toxic dietary and hyperbaric oxygen therapies doubles survival time in cancer model

A team of researchers from the Hyperbaric Biomedical Research Laboratory at the University of South Florida (USF) doubled survival time in an aggressive metastatic cancer model using a novel combination of non-toxic dietary and hyperbaric oxygen therapies.

11 Jun 2015

Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

A previously unknown link between the immune system and the death of motor neurons in Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been discovered by scientists at the CHUM Research Centre and the University of Montreal. The finding paves the way to a whole new approach for finding a drug that can cure or at least slow the progression of such neurodegenerative diseases as ALS, Alzheimer's, Parkinson's and Huntington's diseases.

10 Jun 2015

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Quality control is important - this is not only applicable to industrial production but also true for all life processes. However, whereas an enterprise can start a large-scale recall in case of any doubt, defects in the quality control systems of cells are often fatal.

9 Jun 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Jun 2015

Cytokinetics, The ALS Association expand partnership to fight against ALS

Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.

4 Jun 2015

U of T researchers uncover new insights on genetic causes of ALS

Researchers at the University of Toronto have uncovered new insights on the genetic causes of Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig's disease. These findings could uncover a new way to detect a genetic predisposition to ALS before the disease strikes.

4 Jun 2015

Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

Scientists at Mayo Clinic, Jacksonville, Florida created a novel mouse that exhibits the symptoms and neurodegeneration associated with the most common genetic forms of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), both of which are caused by a mutation in the a gene called C9ORF72.

24 May 2015

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.

14 May 2015

Proteomics helps identify previously unrecognized proteins and pathways in nerve regeneration

Using proteomics techniques to study injured optic nerves, researchers at Boston Children's Hospital have identified previously unrecognized proteins and pathways involved in nerve regeneration. Adding back one of these proteins--the oncogene c-myc--they achieved unprecedented optic nerve regeneration in mice when combined with two other known strategies.

5 May 2015

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease.

28 Apr 2015

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

New research highlights how nerves - whether harmed by disease or traumatic injury - start to die, a discovery that unveils novel targets for developing drugs to slow or halt peripheral neuropathies and devastating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS).

22 Apr 2015

BrainStorm presents positive results from NurOwn phase 2a study in ALS at AAN annual meeting

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C.

21 Apr 2015

Johns Hopkins researchers create the largest library of brain cells from ALS patients

Researchers at Johns Hopkins Medicine have transformed skin cells from patients with Lou Gehrig’s disease, or amyotrophic lateral sclerosis (ALS), into brain cells affected by the progressive, fatal disease and deposited those human-made cells into the first public ALS cell library, enabling scientists to better study the disease.

15 Apr 2015

Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

Low-frequency alternating magnetic fields such as those generated by overhead power lines are considered a potential health risk because epidemiological studies indicate that they may aggravate, among other things, neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

8 Apr 2015

Aging associated with development of dysphagia

Nearly 40 percent of Americans 60 and older are living with a swallowing disorder known as dysphagia. Although it is a major health problem associated with aging, it is unknown whether the condition is a natural part of healthy aging or if it is caused by an age-related disease that has yet to be diagnosed, such as Parkinson's disease or amyotrophic lateral sclerosis (ALS).

8 Apr 2015

Study finds link between neurodegenerative disorders and inflammation

Researchers from McMaster University and the Icahn School of Medicine at Mount Sinai, New York have discovered that a protein associated with neurodegenerative diseases like ALS also plays an important role in the body's natural antiviral response.

30 Mar 2015

Amyotrophic Lateral Sclerosis News and Research

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

ALS ACT initiative to speed discovery of new ALS treatments

Kay E. Davies named recipient of ASHG's 2015 William Allan Award

Stanford researchers find how neurons work together to control movement in people with paralysis

Novel combination of non-toxic dietary and hyperbaric oxygen therapies doubles survival time in cancer model

Immune system linked to death of motor neurons in Amyotrophic lateral sclerosis

Frankfurt researchers decode molecular details that provide better understanding of neurodegenerative diseases

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Cytokinetics, The ALS Association expand partnership to fight against ALS

U of T researchers uncover new insights on genetic causes of ALS

Mayo Clinic scientists create mouse model of ALS, FTD caused by mutations in C9ORF72 gene

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

Proteomics helps identify previously unrecognized proteins and pathways in nerve regeneration

TSRI study provides new insight into preventing diseases that cause vision loss in adults

Discovery unveils novel drug targets to halt peripheral neuropathies, neurodegenerative disorders

BrainStorm presents positive results from NurOwn phase 2a study in ALS at AAN annual meeting

Johns Hopkins researchers create the largest library of brain cells from ALS patients

Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

Aging associated with development of dysphagia

Study finds link between neurodegenerative disorders and inflammation

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News